Table 1 Comparison of the sensitivity and specificity for ≥CIN2 of physician-collected specimens (endocervical), and vaginal self-collected assayed for HR-HPV by AmpFire, Cobas, SeqHPV (95% CIs and the actual patient numbers are in parentheses)
From: Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening
Specimen/High-Risk HPV Test | Sensitivity for ≥ CIN 2 (%) (CI) (n) | Specificity for ≥ CIN 2 (%) (CI) (n) |
|---|---|---|
Clinician Collected / AmpFire | 95.74% (88.85–98.63) (90/94) | 90.77% (90.00–91.49) (5399/5948) |
Self-Collected / AmpFire | 96.81% (90.29–99.17) (91/94) | 89.81% (89.01–90.56) (5342/5948) |
Clinician Collected / Cobas | 92.55% (84.75–96.70) (87/94) | 91.04% (90.28–91.75) (5415/5948) |
Self-Collected / Cobas | 95.74% (88.85–98.63) (90/94) | 88.48% (87.64–89.28) (5263/5948) |
Clinician Collected / SeqHPV | 91.49% (83.44–95.99) (86/94) | 91.27% (90.52–91.97) (5429/5948) |
Self-collected / SeqHPV | 94.68% (87.45–98.03) (89/94) | 90.72% (89.95–90.15) (5396/5948) |
Cytology | 72.34% (62.00–80.83) (68/94) | 96.45% (95.94–96.90%) (5737/5948) |